Cognitive dysfunction in postmenopausal breast cancer patients on aromatase inhibitors

References

• Early Breast Cancer Trialists’ Collaborative Group (EBCTCG). Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: an overview of the randomised trials. Lancet365(9472), 1687–1717 (2005).
   PubMed Web of Science ®Google Scholar
• Morse R, Rodgers J, Verrill M, Kendell K. Neuropsychological functioning following systemic treatment in women treated for breast cancer: a review. Eur. J. Cancer39(16), 2288–2297 (2003).
   PubMed Web of Science ®Google Scholar
• Rapp SR, Espeland MA, Shumaker SA et al. Effect of estrogen plus progestin on global cognitive function in postmenopausal women: the Women’s Health Initiative Memory Study: a randomized controlled trial. JAMA289(20), 2663–2672 (2003).
   PubMed Web of Science ®Google Scholar
• Espeland MA, Rapp SR, Shumaker SA et al. Conjugated equine estrogens and global cognitive function in postmenopausal women: Women’s Health Initiative Memory Study. JAMA291(24), 2959–2968 (2004).
   PubMed Web of Science ®Google Scholar
• Lethaby A, Hogervorst E, Richards M, Yesufu A, Yaffe K. Hormone replacement therapy for cognitive function in postmenopausal women. Cochrane Database Syst. Rev.1, CD003122 (2008).
   Google Scholar
• Honda K, Sawada H, Kihara T et al. Phosphatidylinositol 3-kinase mediates neuroprotection by estrogen in cultured cortical neurons. J. Neurosci. Res.60(3), 321–327 (2000).
   PubMed Web of Science ®Google Scholar
• Schilder CM, Seynaeve C, Beex LV et al. Effects of tamoxifen and exemestane on cognitive functioning of postmenopausal patients with breast cancer: results from the neuropsychological side study of the tamoxifen and exemestane adjuvant multinational trial. J. Clin. Oncol.28(8), 1294–1300 (2010).
   PubMed Web of Science ®Google Scholar
• Dietrich J, Monje M, Wefel J, Meyers C. Clinical patterns and biological correlates of cognitive dysfunction associated with cancer therapy. Oncologist13(12), 1285–1295 (2008).
   PubMed Web of Science ®Google Scholar
• Jenkins V, Shilling V, Deutsch G et al. A 3-year prospective study of the effects of adjuvant treatments on cognition in women with early stage breast cancer. Br. J. Cancer94(6), 828–834 (2006).
   PubMed Web of Science ®Google Scholar
• Ahles TA, Saykin AJ, McDonald BC et al. Longitudinal assessment of cognitive changes associated with adjuvant treatment for breast cancer: impact of age and cognitive reserve. J. Clin. Oncol.28(29), 4434–4440 (2010).
   PubMed Web of Science ®Google Scholar
• Abraham J, Haut MW, Moran MT, Filburn S, Lemiuex S, Kuwabara H. Adjuvant chemotherapy for breast cancer: effects on cerebral white matter seen in diffusion tensor imaging. Clin. Breast Cancer8(1), 88–91 (2008).
   PubMed Web of Science ®Google Scholar
• Deprez S, Amant F, Yigit R et al. Chemotherapy-induced structural changes in cerebral white matter and its correlation with impaired cognitive functioning in breast cancer patients. Hum. Brain Mapp.32(3), 480–493 (2011).
   PubMed Web of Science ®Google Scholar
• Jenkins V, Shilling V, Fallowfield L, Howell A, Hutton S. Does hormone therapy for the treatment of breast cancer have a detrimental effect on memory and cognition? A pilot study. Psychooncology13(1), 61–66 (2004).
   PubMed Web of Science ®Google Scholar
• Differential effects of hormonal therapy on cognition in postmenopausal hormone receptor-positive (HR+) breast cancer (BC) patients (pts). Presented at: ASCO 2011. Chicago, IL, USA, 12 March 2011.
   Google Scholar
• Jenkins VA, Ambroisine LM, Atkins L, Cuzick J, Howell A, Fallowfield LJ. Effects of anastrozole on cognitive performance in postmenopausal women: a randomised, double-blind chemoprevention trial (IBIS II). Lancet Oncol.9(10), 953–961 (2008).
   PubMed Web of Science ®Google Scholar
• Jenkins V, Atkins L, Fallowfield L. Does endocrine therapy for the treatment and prevention of breast cancer affect memory and cognition? Eur. J. Cancer43(9), 1342–1347 (2007).
   PubMed Web of Science ®Google Scholar
• Phillips KA, Ribi K, Sun Z et al. Cognitive function in postmenopausal women receiving adjuvant letrozole or tamoxifen for breast cancer in the BIG 1–98 randomized trial. Breast19(5), 388–395 (2010).
   PubMed Web of Science ®Google Scholar
• Phillips KA, Aldridge J, Ribi K et al. Cognitive function in postmenopausal breast cancer patients one year after completing adjuvant endocrine therapy with letrozole and/or tamoxifen in the BIG 1–98 trial. Breast Cancer Res. Treat.126(1), 221–226 (2011).
   PubMed Web of Science ®Google Scholar
• Hermelink K, Henschel V, Untch M, Bauerfeind I, Lux MP, Munzel K. Short-term effects of treatment-induced hormonal changes on cognitive function in breast cancer patients: results of a multicenter, prospective, longitudinal study. Cancer113(9), 2431–2439 (2008).
   PubMed Web of Science ®Google Scholar
• Bender CM, Sereika SM, Brufsky AM et al. Memory impairments with adjuvant anastrozole versus tamoxifen in women with early-stage breast cancer. Menopause14(6), 995–998 (2007).
   PubMed Web of Science ®Google Scholar
• Schilder CM, Eggens PC, Seynaeve C et al. Neuropsychological functioning in postmenopausal breast cancer patients treated with tamoxifen or exemestane after AC-chemotherapy: cross-sectional findings from the neuropsychological TEAM-side study. Acta Oncol.48(1), 76–85 (2009).
   PubMed Web of Science ®Google Scholar
• Collins B, Mackenzie J, Stewart A, Bielajew C, Verma S. Cognitive effects of hormonal therapy in early stage breast cancer patients: a prospective study. Psychooncology18(8), 811–821 (2009).
   PubMed Web of Science ®Google Scholar
• Loehberg CR, Jud SM, Haeberle L et al. Breast cancer risk assessment in a mammography screening program and participation in the IBIS-II chemoprevention trial. Breast Cancer Res. Treat.121(1), 101–110 (2010).
   PubMed Web of Science ®Google Scholar
• Dunn BK, Ryan A. Phase 3 trials of aromatase inhibitors for breast cancer prevention: following in the path of the selective estrogen receptor modulators. Ann. NY Acad. Sci.1155, 141–161 (2009).
   PubMed Web of Science ®Google Scholar
• Goss PE, Ingle JN, Ales-Martinez JE et al. Exemestane for breast-cancer prevention in postmenopausal women. N. Engl. J. Med.364(25), 2381–2391 (2011).
   PubMed Web of Science ®Google Scholar
• Phillips KA, Ribi K, Fisher R. Do aromatase inhibitors have adverse effects on cognitive function? Breast Cancer Res.13(1), 203 (2011).
   Google Scholar